Commentary

Chemoprevention for Breast Cancer


 

There remain many questions about effective chemopreventive therapy particularly regarding the length of therapy. Emerging data support continued risk reduction with persistent therapy.

Primary care practices have new tools to identify and manage patients at increased risk for breast cancer. Incorporation of the Gail model into the preventive care of selected women could identify patients at high risk for invasive breast cancer who would benefit from chemoprevention and possible multidisciplinary follow-up.

Dr. Anjali Sibley is assistant professor of medicine at Dartmouth Medical School and is in the department of hematology and oncology at Dartmouth Hitchcock Medical Center in Lebanon, N.H. Dr. William E. Golden is professor of medicine and public health at the University of Arkansas, Little Rock. Neither author reported having any conflicts of interest.

Pages

Recommended Reading

Clinical Trial Participation Tied to Improved Breast Cancer Outcomes
MDedge Family Medicine
Depression From Pregnancy Loss Lingers After Healthy Births
MDedge Family Medicine
HIV Prevention, Testing of Nonpregnant Women
MDedge Family Medicine
Makena Price Spike Causes Anger, Fear
MDedge Family Medicine
Obstetric History May Modify 17P's Effectiveness
MDedge Family Medicine
Bone Micrometastases Show No Survival Impact in Early Breast Cancer
MDedge Family Medicine
NCCN Breast Guidelines Stand by Bevacizumab
MDedge Family Medicine
Tryptophan, Tyrosine May Battle Early Postpartum Depression
MDedge Family Medicine
Treating Mood Disorders in Pregnancy – Not an Easy Decision
MDedge Family Medicine
Vocal Cord Dysfunction More Common in Certain Groups
MDedge Family Medicine